|
Coiled Therapeutics PLC - London-based clinical stage oncology company - Giving a clinical trial update, company announces that regarding advanced solid tumour cancers, its brain-penetrant inhibitor AO-252 delivered an 80% clinical benefit rate when transitioned to a twice-daily dosing regimen, compared to 40% observed in the once-daily cohort. The firm says 80% of evaluable patients in the twice-daily cohort achieved tumour stabilisation or regression, with treatment durations exceeding six months. ‘This substantially outperforms the two to three month benchmark typically seen with salvage therapy in this heavily pre-treated population,’ Coiled adds. The company says: ‘A particularly notable result has been observed in a leiomyosarcoma patient, who achieved stable disease after just two cycles of AO-252, despite having received nine prior lines of therapy.’ Leiomyosarcoma is a type of cancer that develops in smooth muscle cells. Chief Executive Officer Sridhar Vempati says: ‘With dose escalation on track for completion in H1 2026 and multiple data readouts expected across the year, we believe 2026 will be a transformational year for Coiled Therapeutics with key data catalysts that will drive value. We look forward to updating shareholders as these milestones are achieved.’ Current stock price: 10.00 pence each, up 18% on Wednesday afternoon in London 12-month change: up 8.1% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
